PHARMACOLOGICAL AND CLINICAL ASPECTS OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION

GAFAROV Rushen Refatovich

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali · 2024-yil

Annotatsiya

Erectile dysfunction (ED) is an important health problem in men associated with reduced quality of life. Implementation of phosphodiesterase type 5 inhibitors (PDE-5 Is) has revolutionized the management of patients with ED and PDE-5Is are currently considered first-line therapy of ED. This paper describes characteristics of the pharmacokinetics, pharmacodynamics and possible clinical side effects of medications from the PDE-5 Is group. PDE-5Is discussed in the article include sildenafil, tadalafil, vardenafil, udenafil, avanafil, lodenafil, mirodenafil, youkenafil, SLx-2101 and simmerafil.

Maqola ma’lumotlari
MualliflarGAFAROV Rushen Refatovich
JurnalJournal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali
Nashr sanasi2024-09-04
Jild9
Son3
TilIngliz

Kalit so‘zlar

ингибиторы фосфодиэстеразы 5 типа, эректильная дисфункция, фармакокинетика, фармакодинамика, побочные эффекты, phosphodiesterase type 5 inhibitors, erectile dysfunction, pharmacokinetics, pharmacodynamics, side effects, fosfodiesteraza 5-turi ingibitorlari, erektil disfunksiya, farmakokinetika, farmakodinamika, nojo'ya ta'sirlar

Ilmiy soha

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali jurnalidan boshqa maqolalar

Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali — barcha maqolalar